ViewRay advanced radiation therapy technology for the treatment of cancer
Earnings Review and Free Research Report: Natus Medical’s Revenue Soared 34.9% Wed, 22 Nov 2017 12:40:00 +0000 Research Desk Line-up: ViewRay Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 22, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Natus Medical Inc. (NASDAQ: BABY ...
ViewRay® to Participate in Upcoming Conferences Tue, 21 Nov 2017 21:01:00 +0000 CLEVELAND , Nov. 21, 2017 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Chris Raanes , Chief Executive Officer, and Ajay Bansal , Chief Financial Officer are scheduled to participate ...
VRAY: Financial Results For Third Quarter 2017. Revising Revenue Guidance Mon, 20 Nov 2017 20:00:00 +0000 On November 13, 2017 VRAY (VRAY) announced third quarter financial results. The firm recorded revenue of little over $12 million for the quarter. Management had originally guided for total sales of 7-8 systems for 2H 2017. We had accordingly estimated revenues of $16.8 million and $30.8 million for Q3 and Q4 of 2017 respectively resulting in an estimate of $47.6 million for 2H 2017. However, the company recorded sales of only two systems during Q3, resulting in lower than anticipated revenue for the quarter. The firm modestly revised their revenue guidance to be between $42 and $47 million for 2017. Based on this revised guidance, we model five installations of the MRIdian systems for the fourth quarter.
ViewRay reports 3Q loss Mon, 13 Nov 2017 12:13:21 +0000 The Oakwood Village, Ohio-based company said it had a loss of 19 cents per share. The radiation therapy systems maker posted revenue of $12.2 million in the period. ViewRay expects full-year revenue in ...
ViewRay Reports Third Quarter 2017 Financial Results Mon, 13 Nov 2017 12:00:00 +0000 Strong Order Momentum in Q3, continuing in Q4 CLEVELAND , Nov. 13, 2017 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the third quarter and nine months ended September ...
ViewRay, Inc. to Host Earnings Call Mon, 13 Nov 2017 11:10:00 +0000 \NEW YORK, NY / ACCESSWIRE / November 13, 2017 / ViewRay, Inc. (NASDAQ: VRAY ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 13, 2017 at 8:30 AM Eastern ...
Washington University Completes Installation of Second MRIdian MR-Guided Radiotherapy System from ViewRay Fri, 10 Nov 2017 22:33:00 +0000 CLEVELAND, Nov. 10, 2017 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today that the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, has completed installation of their new MRIdian Linac. This marks the hospital's second MRIdian system, furthering their leadership role in the delivery of MR-guided radiation therapy. With a focus on improving patient care and outcomes, Siteman Cancer Center has a rich history of utilizing the most advanced medical technologies available.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.